Why the study?
Does detectable hs-cTnT predict death and cardiovascular outcomes in patients with chest pain and stable troponin levels?
Does detectable hs-cTnT predict death and cardiovascular outcomes in patients with chest pain and stable troponin levels?
In patients presenting with chest pain and stable troponin levels, even minimally detectable hs-cTnT is a prognostic marker for increased mortality and cardiovascular risk.
May aid risk stratification in stable chest pain; leaves open whether thresholds should guide therapy.
Among patients with chest pain and stable troponin levels, any detectable level of hs-cTnT is associated with an increased risk of death and cardiovascular outcomes and should merit further attention.
No takes yet. Share an insight, caveat, or question.
Roos et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: